This must-attend event for medical product industry stakeholders brings together regulatory practitioners, industry experts, and government officials to engage on the latest trends and updates in advertising and promotion through panel discussions and case studies.

Practical Takeaways: Explore the current state of off-label promotion, how to evaluate and use real-world evidence, and the increased focus on scientific exchanges.

FDA Speakers: Representatives from CBER, CDER, CDRH, and CVM will provide the latest information on policy, enforcement, and future initiatives.

Peer Interaction: Network with and learn from legal and regulatory experts.

Register by August 1, 2019 and SAVE!

Industry & Firms

  • +$600 for non-members
  • +$100 after 8/1/2019
  • +$100 after 9/12/2019


  • +$100 for non-members
  • +$100 after 8/1/2019
  • +$100 after 9/12/2019


  • +$100 for non-members
  • +$100 after 8/1/2019
  • +$100 after 9/12/2019


  • +$100 for non-members
  • +$100 after 8/1/2019
  • +$100 after 9/12/2019


  • students registration
  • full-time students only
  • transcripts required
Registration Will Open Soon


Are You New to Advertising and Promotion?

Add the half-day training course, Introduction to Advertising and Promotion for Medical Products, to your conference registration to gain a comprehensive overview of the laws and regulations affecting the medical products industries. Add the training course to your registration and save $100 off the combined fees.


Sponsorship opportunities are available. Please let us know if you would like more information.

Gold Sponsor

Silver Sponsor

Silver Sponsor

Last Year’s Agenda

A preliminary agenda will be announced in June 2019.

Day 1

Renaissance Downtown Hotel, 999 Ninth St NW, Washington, DC 20001

Registration and Continental Breakfast | 8:00 – 8:45 AM

Welcome and Opening Remarks | 8:45 – 9:00 AM
Amy Comstock Rick
, President & CEO, Food and Drug Law Institute (FDLI)
Mark Gaydos, VP, NA Gen Med & US Advertising & Promotion, Global Regulatory Affairs, Sanofi and Co-Chair, Advertising & Promotion for Medical Products Conference Planning Committee

Keynote Address | 9:00 – 9:45 AM 
Lauren Silvis, Chief of Staff, Office of the Commissioner, FDA

FDA’s Office of Prescription Drug Promotion (OPDP) will present on the two final guidance documents released this year relating to medical product communications. They will address significant changes and departures from the draft guidance documents as well as FDA’s current thoughts behind the changes.


Christine Corser, Health Science Policy Analyst, Office of Prescription Drug Promotion, CDER, FDA
Elizabeth Pepinsky, Health Science Policy Analyst, Office of Prescription Drug Promotion, CDER, FDA
Moderated by Catherine Gray, Supervisory Consumer Safety Officer, Office of Prescription Drug Promotion, CDER, FDA

Networking & Coffee Break | 10:45 – 11:15 AM

Concurrent Breakout Sessions | 11:15 – 12:30 PM

This panel will discuss the impact of the final guidance on device promotion and how to utilize the guidance in practice. Industry speakers will also discuss the interplay between this guidance and other guidances relating to General/Specific Intended Use, and whether the guidance has changed the analysis of whether a specific claim is within the scope of a general clearance. This session will also explore trends and changes in the way FDA is enforcing these issues.


Vernessa Pollard, Partner, McDermott Will & Emery
Cassie Scherer
, Principal Legal Counsel, Medtronic
Jeffrey Shapiro, Director, Hyman, Phelps & McNamara, PC
Moderated by Sarah Stec, Senior Counsel, Medical Device Regulatory Law, Johnson & Johnson

This session will take a deep dive into how companies have interpreted the final guidance to support promotional and economic communications, including examples of how companies interpret and apply the guidance in new and interesting ways. Industry speakers will also discuss the related policies and procedures companies have developed in effectuating the recommendations in the draft and final guidance documents.     


Timothy Candy, Principal Consultant, Regulatory Affairs, Opus Regulatory, Inc.
Sue Gregory, Managing Counsel, Merck & Co., Inc.
Michael Listgarten, Sr. Associate General Counsel, Genentech, Inc.
Moderated by Heidi Gertner, Partner, Hogan Lovells US LLP

Luncheon | 12:30 – 1:45 PM

Transition | 1:45 – 2:00 PM

Concurrent Breakout Sessions | 2:00 – 3:00 PM

In the advertising and promotion regulatory realm, medical devices and IVDs present challenges for industry that can differ markedly from other products. How can companies walk the line between “research use only” and approved/cleared diagnostic claims? What is the best way to coordinate companion diagnostic marketing claims with the related drug product? This session will walk through specific scenarios and case studies to help practitioners stay on top of advertising and promotion challenges in this fast-changing space.


Karen Becker, Managing Director, Translational and Regulatory Sciences, Precision for Medicine
Jennifer Henderson, Partner, Hogan Lovells US LLP
Allyson B. Mullen, Attorney, Hyman, Phelps & McNamara, PC
Moderated by Michael Swit, Principal, Law Offices of Michael A. Swit

This session will explore less traditional but trending methods of advertising and promotion and related risks and evaluate when a company can be held responsible for such communications. Topics and venues to be discussed include: communications made by parties other than the manufacturer or distributor; use of visual aids such as pipeline charts in promotional booths; banner ads on sites where the product sponsor does not control the content; and co-promotion.


Heather Banuelos, Counsel, King & Spalding LLP
Kai Peters, Partner, Gordon & Rees Scully Mansukhani
Jennifer Romanski, Principal, Porzio, Bromberg & Newman, P.C.

This panel will explore diverse types of communications with patients. Speakers will address the do’s and don’ts regarding drug manufacturer programs involving patients, including patient assistance programs, patient ambassadors, and discussion of investigational drugs with patient advocacy groups. Relevant laws, regulations, recent enforcement actions, and industry best practices for engaging in patient activities will be discussed.


Abraham Gitterman, Associate, Arnold & Porter LLP
Ryan Hohman, Vice President–Public Affairs, Friends of Cancer Research
Paul Savidge, US General Counsel, Spark Therapeutics
Moderated by Mark Gaydos, VP, NA Gen Med & US Advertising & Promotion, Global Regulatory Affairs, Sanofi and Co-Chair, Advertising & Promotion for Medical Products Conference Planning Committee

Networking Break & Coffee Break | 3:00 – 3:30 PM

What are the standards for evaluating data and the processes for gathering data, specifically in the context of promotional utilization? How should real-world evidence studies be designed with promotion in mind? How does real-world evidence fit into the framework of the “Consistent with Labeling” and “Payor Communications” guidance documents? This session will discuss use of real-world evidence in the promotion of medical products, the coalescing standards for regulatory support and product promotion, practices and strategies for companies considering its use, and how manufacturers can avoid communicating false and misleading medical product claims.


Eric Gemmen, Senior Director, Epidemiology & Outcomes Research, Real World Evidence, Real World & Analytics Solutions, IQVIA, Inc.
Colleen Heisey
, Partner, Jones Day
Ellen Schumacher, Executive Director, Commercial Regulatory Affairs, Bristol-Myers Squibb Company
Moderated by Kellie Combs, Partner, Ropes & Gray LLP and Co-Chair, Advertising & Promotion for Medical Products Conference Planning Committee

Networking Reception | 5:00 – 6:30 PM

Day 2

Registration and Continental Breakfast | 8:00 – 8:40 AM

Welcome and Announcements | 8:40 – 8:45 AM
Laura Brown, Director, Educational Programs, FDLI
Kellie Combs, Partner, Ropes & Gray LLP and Co-Chair, Advertising & Promotion for Medical Products Conference Planning Committee

This session will provide an update on First Amendment issues in the promotional realm. Speakers will discuss how FDA’s outlook on product communications, as viewed through the lens of the “Consistent with Labeling” and “Payor Communications” guidance documents and its consideration of real-world evidence, relate to FDA’s current approach to First Amendment issues. Speakers will also consider whether FDA’s perspective on commercial speech differs for drugs versus devices; issues related to commercial speech and exclusivity; and potential First Amendment-related reforms.


Jeffrey Chasnow, Senior Vice President and Associate General Counsel, Pfizer, Inc.
Scott Lassman
, Partner, Goodwin Procter LLP
Peter Pitts, President, Center for Medicine in the Public Interest
Moderated by Kelly Goldberg, Vice President, Law & Senior Counsel for Biopharmaceutical Regulation, PhRMA

FDA officials from the agency’s medical product centers – CDER, CBER, CDRH, and CVM – will discuss recent enforcement actions taken by their offices, the importance of these actions for companies, and enforcement priorities. 


Thomas Abrams, Director, Office of Prescription Drug Promotion, CDER, FDA
Thomas Moskal, Veterinary Medical Officer, Post-Approval Review Team, CVM, FDA 
Lisa Stockbridge, Supervisory Consumer Safety Officer, Advertising and Promotion Labeling Branch, CBER, FDA
Deborah Wolf, Regulatory Counsel, Division of Premarket and Labeling Compliance, CDRH, FDA
Moderated by Wayne Pines, President, Regulatory Services and Healthcare, APCO Worldwide

Networking & Coffee Break | 10:30 – 10:45 AM

Advertising and promotion of FDA-regulated medical products faces scrutiny, compliance challenges, and legal risk from multiple actors in the legal system beyond FDA. Government and industry experts will explore the other sources of compliance obligations and risk, including the FTC, state Attorneys General, state marketing laws and enforcement actions, private litigants in Lanham Act lawsuits, and how drug advertising and promotion, including off-label promotion, impacts mass-tort litigation. Speakers will also explore ways to mitigate risks when facing these challenges. 


John Bentivoglio, Partner, Skadden, Arps, Slate, Meagher & Flom LLP
Richard Cleland, Assistant Director, Bureau of Consumer Protection, Division of Advertising Practices, Federal Trade Commission
Jason Rose, Partner, Venable LLP
Moderated by James Czaban, Partner, Chair, FDA and Medical Products Practice Group, DLA Piper LLP (US)

Transition | 12:00 – 12:15 PM

Facilitated Table Topic Discussions | 12:15 – 1:15 PM

FDA’s social science researchers will offer insight into OPDP’s research program and how it supports OPDP’s work regulating prescription drug promotion. They will also discuss the application of their findings, including how their research affects FDA’s approach to gathering data.


Kevin Betts, Social Science Analyst, Office of Prescription Drug Promotion, CDER, FDA
Amie O’Donoghue, Social Science Analyst, Office of Prescription Drug Promotion, CDER, FDA
Helen Sullivan, Social Science Analyst, Office of Prescription Drug Promotion, CDER, FDA
Moderated by Kathryn Aikin, Social Science Team Leader, Office of Prescription Drug Promotion, CDER, FDA

This panel will address both the visible and less-visible aspects of product promotion on the internet. Speakers will consider the technology behind search engine optimization and metadata, which impacts public perception of a product by presenting content. Speakers will also discuss the utilization of visual promotional communications on social media, including space limited platforms, utilization of influencers, independent bloggers, and native advertising.


Mark duPlessis, Celgene Corporation                                    
Jason Gordon, Partner, Reed Smith LLP
Anne Maher
, Partner, Kleinfeld, Kaplan & Becker, LLP
Moderated by Dale Cooke, President, PhillyCooke Consulting

Conference Adjournment | 3:30 PM

Planning Committee


Paul J. Savidge, Spark Therapeutics
Ellen Shumacher, Bristol-Meyers Squibb Company

Committee Members 

Fadwa Almanakly, Bayer Healthcare Pharmaceuticals
Heather Banuelos, King & Spalding LLP
Rebecca Burnett, Framework Solutions
Kellie B. Combs, Ropes & Gray LLP
Virginia Foley, Opus Regulatory, Inc.
Mark Gaydos, Sanofi
Bryant M. Godfrey, Arnold & Porter LLP
Kelly F. Goldberg, PhRMA
Daniel McHugh, Celgene Corporation
Cynthia L. Meyer, Kleinfeld, Kaplan & Becker, LLP
Lauren Miller, Otsuka America Pharmaceutical, Inc.
Mary Monovoukas, Boston Scientific Corporation
Wayne Pines, APCO Worldwide
Lucy Rose, Lucy Rose & Associates, LLC
Dolores M. Shank-Samiec, Merck & Co., Inc.

Continuing Legal Education

FDLI applies for CLE credits in Ohio, Pennsylvania, and Virginia. These CLE approvals may also be honored by other states; please check with your bar association for guidance. The CLE credits will be posted as they are granted and you can request to be notified when approval is received.

Location and Overnight Accommodations

Conference Location

Renaissance Downtown Hotel
999 Ninth St NW
Washington, DC 20001

Overnight Accommodations

Coming soon.